Archives
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Enhanced arginase activity and the resultant decreases
2025-01-17

Enhanced arginase activity and the resultant decreases in L-arginine levels can also impair T cell mediated immune function and allow tumor growth by limiting the supply of L-arginine needed for the formation of cytotoxic levels of NO by iNOS [10]. Increased arginase expression/activity may also lim
-
Enhancers are short regions of DNA that are bound by
2025-01-16

Enhancers are short regions of DNA that are bound by DNA-binding proteins (TFs) to increase the likelihood of a particular gene to be expressed. Importantly, enhancers can be identified, and classified, by their patterns of chromatin accessibility and of enrichment in certain histone modifications.
-
A Belgian review on perioperative
2025-01-16

A Belgian review [9] (2011) on perioperative management of drugs recommends not using ACEI/ARBs due to the same reason. Another 2014 French [10] publication on the management of antihypertensive drugs in the perioperative period suggests withholding this medication before surgery even though they a
-
The major phase trial NCT enrolled participants with
2025-01-16

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
-
Recent studies suggest that A caused synapse damage as a
2025-01-16

Recent studies suggest that Aβ caused synapse damage as a consequence of aberrant cell signalling. As synthetic Aβ42 monomers activate the phosphatidylinositol-3-kinase pathway (Giuffrida et al., 2009) and insulin signalling (Giuffrida et al., 2012) it is possible that Aβ monomers and Aβ oligomers a
-
hesperidin pub med It remains to elucidate whether proteolyt
2025-01-16

It remains to elucidate whether proteolytic activity is the cause or the consequence of changing levels of peptidergic substrates. In fact, in some cases, the expression of the enzyme does not necessarily parallel with its activity [26], [55], [57] and other factors such as a definite biochemical en
-
br A and tau in Alzheimer s
2025-01-16

Aβ and tau in Alzheimer's disease The two classical histopathological hallmarks of AD are extracellular insoluble Aβ deposits, known as Aβ plaques, and intracellular accumulations of insoluble microtubule-associated tau protein, known as neurofibrillary tangles [14]. Aβ peptides are produced as a
-
Liao and van Linden et al divided the gap between
2025-01-16

Liao [47] and van Linden et al. [48] divided the gap between the N-terminal and C-terminal lobes into a front cleft or pocket, a gate area, and a back cleft. The back pocket corresponds to the gate area and the back cleft. The front cleft includes the Gly-rich loop, the hinge, the linker connecting
-
The mechanisms that control Ahr transcription
2025-01-16

The mechanisms that control Ahr transcription are poorly understood, especially when considering cell type-specific regulation. A recent report suggested that the Ahr transcription might be directly promoted by RORγt [retinoic Caffeine receptor (RAR)-related orphan receptor γt] based on ChIP-Seq an
-
br AHR expression in cancer Perhaps the earliest
2025-01-16

AHR expression in cancer Perhaps the earliest indicator that the AHR might play an ongoing role in tumorigenesis, independent of its role in generating mutations, was the demonstration that non-genotoxic 2,3,7,8-tetrachlorodibenzo(p)dioxin (TCDD) is a carcinogen in animals and humans [7]. Althoug
-
Further examination of these vmat IR cells shows that they
2025-01-16

Further examination of these vmat-IR cells shows that they are also positive for vimentin (vim-IR) (Fig. 3A). However, within any one cell there may be a region of weaker vmat-IR, suggesting sub-cellular localization. As also shown in Fig. 3B and C not all vim-IR cells are vmat-IR suggesting that th
-
Our results showed that oral
2025-01-16

Our results showed that oral administration of cordycepin, in the concentrations of 5 and 10mg/kg for 3weeks, exerted no influence on body weight and hippocampus weight in mice. Although some reports have pointed out that cordycepin had toxic effects because it may be potential for inducing cell dea
-
Luciferase Immunoprecipitation Systems LIPS which utilizes r
2025-01-16

Luciferase Immunoprecipitation Systems (LIPS), which utilizes recombinant antigens fused to the enzyme reporter Renilla luciferase (Ruc) to detect patient antibodies, provides a unique platform to investigate SGX523 directed against a variety of antigenic targets [25]. Previously, LIPS has been used
-
The gene SRD A encodes the reductase
2025-01-16

The gene SRD5A2 encodes the 5-α-reductase enzyme, which converts testosterone into dihydrotestosterone. Although dihydrotestosterone levels are considerably lower than testosterone, dihydrotestosterone has a five-fold stronger binding capacity to the androgen receptor and, thereby, a considerably mo
-
br Materials and methods All animal experiments
2025-01-16

Materials and methods All animal experiments were performed using the recommendations of the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and approved by the University of Colorado—Denver Institutional Animal Care and Use Committee. Adult male Sprague—Dawley
16055 records 25/1071 page Previous Next First page 上5页 2122232425 下5页 Last page